Swiss cancer giant Novartis (NOVN: VX) and German drugmaker Bayer (BAYN: DE) are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024.
Kicking off on May 31 in Chicago, USA, the annual meeting of the American Society of Clinical Oncology (ASCO) will feature thousands of abstracts and numerous discussions on the latest research in this therapy area.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze